^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL19 overexpression

    i
    Other names: CCL19, CKb11, ELC, exodus-3, MIP-3b, SCYA19, Chemokine (C-C motif) ligand 19
    Entrez ID:
    6363
    Related biomarkers:
    Expression
    Others
    over2years
    Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy (ASH 2021)
    The results here reported indicate that pts with a favorable immune signature could derive maximal benefit from a first-line chemo-free treatment approach with single agent Rituximab, achieving and maintaining complete remission in the long term, irrespective of the tumor burden and other clinical variables. Thus, profiling of FL microenvironment with T-GEP could provide a useful tool for selecting patients who may be suitable for a chemo-free upfront treatment with anti CD20 immunotherapy.
    Clinical • IO biomarker
    |
    CCL19 (C-C Motif Chemokine Ligand 19) • CCL2 (Chemokine (C-C motif) ligand 2) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL17A (Interleukin 17A) • CCL22 (C-C Motif Chemokine Ligand 22) • IL17RB (Interleukin 17 Receptor B)
    |
    CD20 expression • CD20 overexpression • CCL19 overexpression • 6-gene signature
    |
    Rituxan (rituximab)